Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
View stock
VS
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
View stock

Stock highlights

Stock comparison highlights
Stock name
CertaraAbbVie
Last price
$9.60$274.36
Currency
USD
USD
$1.4B$497B
-79.42
-$0.43$3.54
1.410.28
0$6.83
02.46%
Sector
HealthHealth
Employees
1,54657,000
Ticker
$CERT$ABBV
Primary listing
NASDAQNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $CERT or $ABBV on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.